Has “ high risk ” become a new disease?

As I was working on the post I published yesterday, I ran into a very interesting 2015 editorial by a Finnish professor on the issue of HIGH RISK and decided it was worth a post of its own, before I go on and finnish, I mean, finish! the bone microenvironment post.    Here’s the link: goo.gl/CWAexK Prof. Järvinen argues that “high risk” has become a disease today. That is, relatively healthy people can start seeing themselves as no longer relatively healthy. AND, he adds, “almost every treatment has inherent risks.” Who can determine the threshold for “high risk”? Doctors? And what if patients disagree? Well, check out  what he says about that, in the section titled: “Understanding risk: are the blind leading the blind?”: “If we assume doctors are truly more competent in making value judgements about the lives of their patients than the patients sitting in front of them, should we not have proof that doctors can do the job? Sadly, despite medical education and clinical experience, doctors do not seem to possess the required skill.” Wow. Once again, we run into the issue of statistics, which tell you that you are at “high risk” of developing this or that if you fall into such and such a category. This has to have an impact on our mental health, among other things. Has to. And we know how much stress is related to a bunch of cancers, including myeloma. Perhaps it’s ...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll high risk Prof. Järvinen Source Type: blogs

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
nni Monteleone Cross-talk between cancer cells and the immune cells occurring in the tumor microenvironment is crucial in promoting signals that foster tumor growth and metastasis. Both cancer cells and immune cells secrete various interleukins (IL), which, either directly or indirectly, stimulate cancer-cell proliferation, survival, and diffusion, as well as contribute to sculpt the immune microenvironment, thereby amplifying tumorigenic stimuli. IL-34, a cytokine produced by a wide range of cells, has been initially involved in the control of differentiation, proliferation, and survival of myeloid cells. More recent ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionLncRNA MALAT1 expedited MM tumorigenesis, invasion, and glycolysis via miR-1271-5p/SOX13 axis. MALAT1 might contribute to the therapy of MM as a promising indicator.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to explore the heterogeneity of circRNA expression pattern via microarray, and further evaluate the potential of 10 specific circRNAs as diagnostic and prognostic biomarkers in multiple myelom...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
sabeth Ersvær Immunomodulatory drugs (IMiDs) are used in the treatment of hematological malignancies, especially multiple myeloma. IMiDs have direct anticancer effects but also indirect effects via cancer-supporting stromal cells. Monocytes are a stromal cell subset whose metabolism is modulated by the microenvironment, and they communicate with neighboring cells through extracellular release of soluble mediators. Toll-like receptor 4 (TLR4) is then a common regulator of monocyte metabolism and mediator release. Our aim was to investigate IMiD effects on these two monocyte functions. We compared effects of thalid...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
CONCLUSIONS: Our findings indicate that combined blockade of PD-1 and TGF-b may be useful for the treatment of MM. PMID: 31941832 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
After the Twin Towers fell on Sept. 11, 2001, the thousands of people involved in rescue-and-cleanup efforts were exposed to carcinogens and other toxins as they breathed in contaminated air and dug through industrial rubble. Studies completed since then have shown elevated rates of conditions including multiple myeloma, prostate cancer and thyroid cancer among 9/11 responders and those who worked near the site. A new study published Jan. 14 in the journal JNCI Cancer Spectrum adds another to that list: leukemia. “After about 12 years of follow-up, there was an increase in the rate of all cancers combined, and separa...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer Research Source Type: news
CONCLUSIONS: This study provides the basis for studying the addition of JAK inhibitors to improve the efficacy of immunomodulatory agents with steroids for treating myeloma patients but perhaps can also be expanded for treating other cancer patients that are refractory to this class of drugs. PMID: 31937615 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsThis study is one of the first to apply the EORTC QLU-C10D to a heterogeneous group of cancer patients. Results can be used to more efficiently target care towards factors influencing HRQoL. Furthermore, it enhances our understanding of how the EORTC QLU-C10D performs across cancer types, supporting its use in cost –utility analyses.
Source: Quality of Life Research - Category: Health Management Source Type: research
SUMMARY The increasing prevalence of neoplasias is associated with new clinical challenges, one of which is acute kidney injury (AKI). In addition to possibly constituting a clinical emergency, kidney failure significantly interferes with the choice and continuation of antineoplastic therapy, with prognostic implications in cancer patients. Some types of neoplasia are more susceptible to AKI, such as multiple myeloma and renal carcinoma. In cancer patients, AKI can be divided into pre-renal, renal (intrinsic), and post-renal. Conventional platinum-based chemotherapy and new targeted therapy agents against cancer are exampl...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
More News: Blogging | Cancer | Cancer & Oncology | Education | Eyes | Finland Health | Men | Myeloma | Statistics | Universities & Medical Training